The Evolution of Biologics Administration From Intravenous to Subcutaneous: Treatments for Inflammatory Bowel Disease Go Home

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
² Department of Gastroenterology, Besançon University Hospital, Bourgogne-Franche-Comté University, Besançon, France.
³ Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.
⁴ Department of Biomedical Sciences, Humanitas University, Milan, Italy; IBD Center, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy. Electronic address: sdanese@hotmail.com.

Editorial

Virginia Solitano et al. Gastroenterology. 2021 Jun.

. 2021 Jun;160(7):2244-2247.

doi: 10.1053/j.gastro.2021.03.038. Epub 2021 Mar 25.

¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
² Department of Gastroenterology, Besançon University Hospital, Bourgogne-Franche-Comté University, Besançon, France.
³ Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.
⁴ Department of Biomedical Sciences, Humanitas University, Milan, Italy; IBD Center, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy. Electronic address: sdanese@hotmail.com.

No abstract available

Comment on

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.
Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, Pukitis A, Horynski M, Farkas K, Kierkus J, Kowalski M, Lee SJ, Kim SH, Suh JH, Kim MR, Lee SG, Ye BD, Reinisch W. Schreiber S, et al. Gastroenterology. 2021 Jun;160(7):2340-2353. doi: 10.1053/j.gastro.2021.02.068. Epub 2021 Mar 5. Gastroenterology. 2021. PMID: 33676969 Clinical Trial.